Abstracts tagged "gout"

Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 2072 • 2017 ACR/ARHP Annual Meeting
A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Hyun A Lee¹, Sang-In Park¹, Seonghae Yoon², Makoto Onohara³, Jeongeun Choi⁴, Kyung-Sang Yu¹ and Howard Lee¹, ¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ²Clinical Trials Center, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. In…
Abstract Number: 170 • 2017 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes
Hirotaka Matsuo¹, Akiyoshi Nakayama², Hirofumi Nakaoka³, Ken Yamamoto⁴, Masayuki Sakiyama⁵, Amara Shaukat⁶, Yu Toyoda⁷, Yukinori Okada⁸, Yoichiro Kamatani⁹, Masahiro Nakatochi¹⁰, Takahiro Nakamura⁵, Tappei Takada⁷, Hiroshi Nakashima⁵, Seiko Shimizu⁵, Makoto Kawaguchi⁵, Asahi Hishida¹¹, Kenji Wakai¹¹, Blanka Stiburkova¹², Karel Pavelka¹³, Lisa K. Stamp¹⁴, Nicola Dalbeth¹⁵, Tatsuo Hosoya¹⁶, Michiaki Kubo⁹, Hiroshi Ooyama¹⁷, Toru Shimizu¹⁸, Kimiyoshi Ichida¹⁹, Tony R. Merriman²⁰ and Nariyoshi Shinomiya²¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Dept Integrative Physiol, National Defense Med College, Tokorozawa, Japan, ³National Inst Genet, Mishima, Japan, ⁴Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ⁵National Defense Med College, Tokorozawa, Japan, ⁶Univ Otago, Dunedin, New Zealand, ⁷Univ Tokyo Hosp, Tokyo, Japan, ⁸Osaka University, Osaka, Japan, ⁹Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹⁰Nagoya Univ Hosp, Nagoya, Japan, ¹¹Nagoya Univ Grad Sch Med, Nagoya, Japan, ¹²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Rheumatology, Prague, Czech Republic, ¹⁴University of Otago, Christchurch, New Zealand, ¹⁵University of Auckland, Auckland, New Zealand, ¹⁶Jikei Univ Sch Med, Tokyo, Japan, ¹⁷Ryougoku East Gate Clin, Tokyo, Japan, ¹⁸Kyoto Industr Health Assoc, Kyoto, Japan, ¹⁹Tokyo Univ Pharmacy Life Sci, Tokyo, Japan, ²⁰Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²¹National Defense Med College, Saitama, Japan
Background/Purpose: We performed a genome-wide association study (GWAS) of gout and its subtypes to identify novel gout loci including those that are subtype-specific. Methods: Putative…
Abstract Number: 1127 • 2017 ACR/ARHP Annual Meeting
Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set
Amara Shaukat¹, Tim Jansen², M. Janssen³, Leo .A.B. Joosten⁴, Timothy Radstake⁵, Philip Riches⁶, Anne-Kathrin Tausche⁷, Jennie Harre Hindmarsh⁸, Nicola Dalbeth⁹, Lisa K. Stamp¹⁰ and Tony R. Merriman¹¹, ¹Univ Otago, Dunedin, New Zealand, ²VieCuri Medical Center, Venlo, Netherlands, ³Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ⁴Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶University of Edinburgh, Edinburgh, United Kingdom, ⁷Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁸Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁹University of Auckland, Auckland, New Zealand, ¹⁰University of Otago, Christchurch, New Zealand, ¹¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Gout results from formation of monosodium urate (MSU) crystals in the presence of hyperuricemia. Genome wide association studies have provided significant insights into hyperuricemia,…
Abstract Number: 2073 • 2017 ACR/ARHP Annual Meeting
Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Nicola Dalbeth⁴, Martin Englund⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴University of Auckland, Auckland, New Zealand, ⁵Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is the most common form of arthritis worldwide. Hyperuricemia is a crucial risk factor resulting in accumulation of uric acid (s-UA) crystals in…
Abstract Number: 200 • 2017 ACR/ARHP Annual Meeting
Implementation and Evaluation of a Novel Nurse-Led Telemedicine Intervention for Dose Escalation of Urate-Lowering Therapy in Gout: A Clinical Practice Improvement Project
Sen Hee Tay^1,2, Bernadette Poh Lee Low³, Pamela Shi Hui Tan², Zhi Wei Khong², Siew Hwa Chong⁴, Amelia Santosa^1,2, Anita Yee Nah Lim^1,2 and Gim Gee Teng^2,5, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, ³Division of Primary Care, Department of Care Integration and Alliance, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ⁴Clinical Nursing Unit, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ⁵Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, Singapore
Background/Purpose: Urate-lowering therapy (ULT) is the mainstay of gout treatment. In our clinics, time to achieve target serum urate (SU) level during ULT titration was…
Abstract Number: 1128 • 2017 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
Wen-Ching Lan, Kuang-Hui Yu, Shue-Fen Luo, Chang-Fu Kuo and Tien-Ming Chan, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Appropriate dose of urate-lowering therapy (ULT) is needed for gout patients to dissolve existing urate crystals to prevent acute gout attacks and reduce the…
Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Jae-Bum Jun¹, Howard Lee², Chang-Hee Suh³, Chang Keun Lee⁴, Dong Wook Kim⁵, Jung-Yoon Choe⁶, Sang-Heon Lee⁷, Sang-Hyon Kim⁸, Seung-Jae Hong⁹, So-Young Bang¹⁰, Sung Jae Choi¹¹, Yong-Beom Park¹², Makoto Onohara¹³, Jeongeun Choi¹⁴, Jung Soo Song¹⁵ and Won Park¹⁶, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine,, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁸Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ⁹Department of Rheumatology, Kyung Hee University Medical Center, Seoul, Korea, Republic of (South), ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹¹Internal Medicine, Korea University Medical Center, Seoul, Korea, Republic of (South), ¹²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ¹³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ¹⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ¹⁵Rheumatology, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Abstract Number: 250 • 2017 ACR/ARHP Annual Meeting
An Ultrasonographic Study for Investigating Relationships with the Signs of Uric Deposition and Bone Erosion in Patients with Hyperuricemia
Ikuko Tanaka¹, Takashi Kato², Motokazu Kai³, Kunikazu Ogawa³, Hisaji Oshima⁴ and Shigenori Tamaki⁵, ¹NAGOYA Rheumatology Clinic, Nagoya, Japan, ²Department of Radiology, National Center for Geratrics and Gerontology, Obu, Japan, ³Mie Rheumatology Clinic, Suzuka, Japan, ⁴Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ⁵Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: Joint ultrasonography (US) is a noninvasive examination that can evaluate arthritis and uric acid deposition at gout attacks. The purpose of this study was…
Abstract Number: 1129 • 2017 ACR/ARHP Annual Meeting
Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Laura Ranieri¹, Carolina Contero², Pedro Zapater^3,4 and Mariano Andrés^1,5, ¹Sección de Reumatología, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²Departamento de Medicina Clínica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ³Sección de Farmacología Clínica, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ⁴Departamento de Farmacología, Pediatría y Química Orgánica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ⁵Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Diuretics have been associated with impaired response to allopurinol and refractoriness in gout, but whether this stills after new urate-lowering treatments (ULT) and treat-to-target…
Abstract Number: 2075 • 2017 ACR/ARHP Annual Meeting
The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
Hye Won Kim¹, Eun-Jeong Yoon², Seok Hoon Jeong² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine,Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Severance Hospital, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Accumulating evidence indicates that gut microbiota interact with gout but it is still unknown how the uric acid lowering treatment (ULT) affects to the…
Abstract Number: 350 • 2017 ACR/ARHP Annual Meeting
Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State
William J. Taylor¹, Nicola Dalbeth², Kenneth Saag³, Jasvinder A. Singh⁴, Elizabeth J. Rahn⁵, Amy S. Mudano⁶, Yi-Hsing Chen⁷, Ching-Tsai Lin⁸, Paul Tan², Worawit Louthrenoo⁹, Janitzia Vazquez-Mellado¹⁰, Hansel Hernández-Llinas¹¹, Tuhina Neogi¹², Ana Beatriz Vargas-Santos¹², Geraldo Castelar-Pinheiro¹³, Rodrigo B. Chaves-Amorim¹³, Till Uhlig¹⁴, Hilde B Hammer¹⁴, Maxim Eliseev¹⁵, Fernando Perez-Ruiz¹⁶, Lorenzo Cavagna¹⁷, Geraldine M. McCarthy¹⁸, Lisa K. Stamp¹⁹, Martijin Gerritsen²⁰, Viktoria Fana²¹, Francisca Sivera²² and Angelo L. Gaffo⁵, ¹University of Otago, Wellington, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁹Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ¹⁰Rheumatology, Hospital General de Mexico, Mexico City, Mexico, ¹¹Hospital General de Mexico, Mexico City, Mexico, ¹²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ¹³Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵V. A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ¹⁶Servicio de Reumatología, Vizcaya, Spain, ¹⁷Division of Rheumatology, University and IRCCS Policlinico S. Matteo, Pavia, Italy, ¹⁸Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁹University of Otago, Christchurch, New Zealand, ²⁰Westfries Gasthuis, Hoorn, Netherlands, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain
Background/Purpose: Treatment targets for gout generally focus on serum urate, but patient-centred targets may be equally important. We seek to determine the relationship between gout…
Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting
Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol
Thomas Bardin^1,2,3, Quang Nguyen Dinh¹, Khoi Tran Minh¹, Nghia Le Hieu¹, Minh Do Duc⁴, Pascal Richette^5,6 and Matthieu Resche-Rigon^3,7, ¹French-Vietnamese Gout Research Center, Ho Chi Minh City, Viet Nam, ²Rheumatology, Hôpital Lariboisière, Paris, France, ³Université Paris Diderot, Paris, France, ⁴Molecular Biology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam, ⁵Rhumatologie, Hôpital Lariboisière, Paris, France, ⁶Rheumatology Department, Université Paris Diderot, Paris, France, ⁷Biostatistics, Hôpital Saint-Louis, Paris, France
Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…
Abstract Number: 2076 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Allopurinol Versus Febuxostat in Preventing Incident Dementia in the Elderly
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Previous studies of hyperuricemia and dementia have provided contradictory findings, ranging from reduced to increased risk. Our objective was to assess the comparative effectiveness…
Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Aprajita Jagpal¹, Nicola Dalbeth², William J. Taylor³, Kenneth Saag¹, Jasvinder A. Singh⁴, Amy S. Mudano⁵, Elizabeth J. Rahn⁶ and Angelo L. Gaffo⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].